Allotment

Lenskart Solutions IPO is a book-built public issue with a total value of ₹7,278.02 crore. The IPO includes a fresh issue of 5.35 crore equity shares, raising ₹2,150.38 crore, along with an offer for sale of 12.76 crore shares worth ₹5,127.64 crore.
The IPO was open for subscription from October 31, 2025, to November 4, 2025. The allotment of shares was completed on November 6, 2025, and the company’s shares were listed on both the BSE and NSE on November 10, 2025.
The price band for the IPO was fixed at ₹402 per share. One lot consisted of 37 shares. Retail investors had to invest a minimum of ₹14,874 for one lot. For sNII investors, the minimum application size was 14 lots (518 shares), requiring an investment of ₹2,08,236. bNII investors needed to apply for 68 lots (2,516 shares), amounting to ₹10,11,432.
The IPO also reserved up to 3,91,644 shares for employees, which were offered at a discount of ₹19 per share compared to the issue price.
The issue was managed by Kotak Mahindra Capital Company Limited as the book-running lead manager, while MUFG Intime India Private Limited handled the registrar responsibilities.
For complete and detailed information, investors are advised to refer to the Lenskart Solutions IPO RHP.
₹4020%
Open
HIgh - Low
Previous Close
Total Traded Value
52 Weeks High
52 Weeks Low
Updates On
IPO. Open
IPO. Close
IPO. Price
IPO Market price
| IPO Date | 10 Nov |
| IPO Listing Date | 10 Nov |
| IPO Face Value | ₹2.00 per share |
| IPO Price Range | ₹402.00 |
| IPO Issue Size | 18,10,58,478 shares |
| IPO Sale Type | Fresh Capital-cum-Offer for Sale |
| Employee Discount | ₹19.00 |
| IPO Issue Type | Book Building IPO |
| IPO Listing | BSE, NSE Platform |
| Share Holding Pre Issue | 1,68,10,15,590 shares |
| IPO Open Date | 31 Oct |
| IPO Close Date | 4 Nov |
| IPO Allotment (Tentative) | 6 Nov |
| Refunds | 7 Nov |
| Credit to Demat Account | 7 Nov |
| IPO Listing Date | 10 Nov |
| Category | Offer |
|---|---|
| QIB Shares Offered | 13,55,04,020 |
| NII (HNI) Shares Offered | 2,71,00,803 |
| Retail Shares Offered | 1,80,67,202 |
Investors can bid for a minimum of 37 shares, with additional shares in multiples of 37.
| Application | Lots | Share | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 37 | ₹14,874 |
| Retail (Max) | 13 | 481 | ₹1,93,362 |
| S-HNI (Min) | 14 | 518 | ₹2,08,236 |
| S-HNI (Max) | 67 | 2,479 | ₹9,96,558 |
| B-HNI (Min) | 68 | 2,516 | ₹10,11,432 |
Lenskart Solutions Ltd., founded in 2008, is a technology-driven eyewear company that designs, manufactures, and sells prescription glasses, sunglasses, contact lenses, and related accessories. India is its main market, and according to the Redseer Report, Lenskart sold the highest number of prescription eyeglasses in India in FY 2025.
The company follows a direct-to-consumer model, offering a wide range of eyewear under its own brands and sub-brands for all ages and price points. In FY 2025, Lenskart launched 105 new collections, including collaborations with well-known brands and celebrities.
As of March 31, 2025, Lenskart operated 2,723 stores worldwide—2,067 in India and 656 abroad. In India, 1,757 stores are company-owned and 310 are franchised. The company also provides remote eye testing services through 136 optometrists across 168 stores, including locations in Japan and Thailand.
Its manufacturing facilities are located in Bhiwadi and Gurugram, with additional regional facilities in Singapore and the UAE. This allows the company to offer next-day delivery in 40 Indian cities and three-day delivery in 69 cities for single-vision prescription eyewear.
Lenskart’s revenue has grown steadily: ₹37,880.28 million in FY 2023, ₹54,277.03 million in FY 2024, and ₹66,525.17 million in FY 2025. Its apps have been downloaded over 100 million times, supported by a technology team of 532 employees.
Key Strengths
Centralized supply chain and in-house manufacturing
In-house frame and lens engineering capabilities
Direct-to-consumer business model
Customer-focused product design
Strong portfolio of owned eyewear brands
Technology-driven operations and retail experience
Omnichannel retail presence
Consistent revenue and EBITDA growth over multiple years
| Assets | 10,845.68 | 10,471.02 | 9,531.02 |
| Total Income | 1,946.10 | 7,009.28 | 5,609.87 |
| Profit After Tax | 61.17 | 297.34 | -10.15 |
| EBITDA | 336.63 | 971.06 | 672.09 |
| NET Worth | 6,176.87 | 6,108.30 | 5,642.38 |
| Reserves and Surplus | 5,855.43 | 5,795.00 | 5,466.50 |
| Total Borrowing | 335.48 | 345.94 | 497.15 |
| ROE | - |
| ROCE | 13.84% |
| Debt/Equity | - |
| RoNW | 4.84 |
| PAT Margin | - |
| EBITDA Margin | 14.60% |
| Price to Book Value | 11.03 |
IPO Objects of the Issue
| S.No. | Objects of the ipo Resources Detail | IPO Amount |
|---|---|---|
| 1 | Funding capital expenditure requirements for the purchase of equipment/machineries | - |
| 2 | To meet out the expenses of Working Capital Requirement | - |
| 3 | To meet out the General Corporate Purposes; | 683.13 |
| 4 | Offer for Sale (OFS) | - |
Lenskart Solutions Ltd.
Plot No. 151, Okhla Industrial Estate, Phase III
Delhi, New Delhi – 110020
Phone: +91 124 429 3191
Email: compliance.officer@lenskart.co
Website: www.lenskart.com
IPO Registrar
MUFG Intime India Pvt. Ltd.
Phone: +91-22-4918 6270
Email: lenskart.ipo@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html
Lenskart Solutions IPO was a book-built issue worth ₹7,278.02 crore, consisting of a fresh issue of 5.35 crore equity shares and an offer for sale of 12.76 crore shares.
The IPO opened on October 31, 2025, and closed on November 4, 2025. Lenskart shares were listed on both BSE and NSE on November 10, 2025.
The issue price was fixed at ₹402 per share with a lot size of 37 shares. Retail investors needed to invest a minimum of ₹14,874 for one lot.
The IPO reserved up to 3,91,644 equity shares for eligible employees, offering a discount of ₹19 per share compared to the final issue price.
Lenskart Solutions is a technology-driven eyewear company offering glasses, sunglasses, and contact lenses, and it was India’s largest seller of prescription eyewear by volume in FY2025.